Science Bridges: Bradford-China Programme for Pharmaceutical Sciences and Medical Technology

该项目侧重于开发符合中英两国政府各自医疗服务政策和相关行业（如糖尿病、感染控制、中医药和医疗器械）战略重点的产品。其总体目的将是为这些需要提供有效的解决办法。预计成果将是新的疗法、增强的生物材料和医疗设备，以及加速新药/医疗设备的发现和商业化的过程的应用和验证。我们有两个主要的主题：制药科学和医疗技术。在第一个主题中，重点将放在中医，在第二个主题中，生物医学应用材料和相关设备。所有的项目活动都将由布拉德福德的团队参与（其他英国大学、卫生服务机构和公司在适当的时候加强），并确定中国领先的大学和组织。依托大华银行与中国学术界之间现有的紧密联系，我们的目标是通过促进中英两国在制药科学（特别是药物发现和输送）和医疗技术方面的开放式创新，加快产品的发明、设计和开发，以满足中英两国的共同需求。这将通过三项主要活动来解决：(i)开发原型和产品的开放创新项目计划，（ii）基于两个主题的互惠培训计划，以及（iii）开发最先进的知识和商业网络。我们还将提供管理利用成果的手段。每个主题都与布拉德福德的领先研究和KT领域相关：制药科学[制药，生物成像（www.ipi.ac.uk）和药物发现与开发（www.cancer.brad.ac.uk）]和先进材料工程[聚合物工程（www.polyeng.com），国际领先的聚合物IRC的一部分]。在过去的两年中，这些小组开发了令人兴奋的第三个联合研究领域，医疗保健技术-包括最近的药物工程科学联合主席，以及合作研究和商业化项目（见跟踪记录）。这三个R&KT领域都与中国领先的大学和合作组织有广泛的联系，但正在发展（有时是相互联系的），如Medilink Y&H有限公司，该公司代表英国贸工部在与中国的健康技术合作伙伴关系中发挥主要作用，以帮助包括中小企业在内的区域高科技公司开发机会和产品。

The programme focusses on the development of products aligned with the strategic priorities of both the Chinese and British governments in their respective health delivery policies and associated industries (e.g. diabetes, infection control, traditional Chinese medicine (TCM) and medical devices). Its overall purpose will be to provide effective solutions to these needs. Outcomes are expected to be new therapies, enhanced biomaterials and medical devices, and the application and validation of processes to accelerate the discovery and commercialization of new drugs/ medical devices. We have two major Themes: Pharmaceutical Sciences and Medical Technology. In the first Theme, emphasis will be placed on Traditional Chinese Medicine, and in the second Theme, materials for biomedical applications, and related devices. All the programme activities will involve Bradford-based teams (strengthened by other UK universities, Health Services and companies whenever appropriate) and identified leading Chinese universities and organisations. Building on existing strong links between UoB and Chinese academia, we aim to accelerate product invention, design, and development through stimulating open innovation between the UK and China, for Pharmaceutical Sciences - particularly drug discovery and delivery - and Medical Technology, meeting aligned needs of the UK and China. This will be addressed by three main activities: (i) an Open Innovation project scheme to develop prototypes and products, (ii) reciprocal training programmes based on the two Themes, and (iii) developing state-of-the-art knowledge and commercial networks. We will also provide means for managing exploitation of the outcomes.Each Theme is associated with leading research and KT areas in Bradford: Pharmaceutical Sciences [pharmaceutics, bioimaging (www.ipi.ac.uk) and drug discovery & development (www.cancer.brad.ac.uk)] and Advanced Materials Engineering [polymer engineering (www.polyeng.com), part of the internationally leading Polymer IRC]. Over the past 2 years these groups have developed an exciting third area of combined research, Healthcare Technologies - including a recent joint Chair in Pharmaceutical Engineering Science, and collaborative research and commercialisation projects (see Track Record). All three R&KT areas have extensive but developing (and sometimes connected) links with leading Chinese Universities and co-operative organisations such as Medilink Y&H Ltd, which is taking a major lead on behalf of UKTI on health technology partnerships with China, to help regional high technology companies, including SMEs, develop opportunities and products.